StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

Equities researchers at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Friday. The brokerage set a “sell” rating on the stock.

A number of other brokerages have also recently commented on CANF. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st.

Can-Fite BioPharma Stock Performance

Shares of NYSE CANF opened at $1.57 on Friday. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69. The company has a market cap of $5.56 million, a PE ratio of -0.88 and a beta of 1.36. The business has a 50-day simple moving average of $1.81 and a two-hundred day simple moving average of $2.32.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC boosted its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.